Endocytosis of ABCG2 drug transporter caused by binding of 5D3 antibody: Trafficking mechanisms and intracellular fate

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1853, Issue 8, 2015, Pages 1759-1771

  Studzian, Maciej ^a   Bartosz, Grzegorz ^a   Pulaski, Lukasz ^a,b  

^a UNIVERSITY OF LODZ   (Poland)

^b INSTITUTE OF MEDICAL BIOLOGY   (Poland)

Author keywords

5D3; ABCG2; Antibody; Endocytosis; Trafficking

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; EPITOPE; HYBRID PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 5D3; UNCLASSIFIED DRUG; ABCG2 PROTEIN, HUMAN; CAVEOLIN 1; CHOLESTEROL; CLATHRIN; PROTEIN BINDING; TUMOR PROTEIN;

ACTIN FILAMENT; ANTIGEN BINDING; ARTICLE; CELL DISRUPTION; CELL FATE; CELL MEMBRANE; CELL PERMEABILIZATION; CELL STRUCTURE; CELL SURFACE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DEPOLYMERIZATION; ENDOCYTOSIS; ENDOSOME; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; INTERNALIZATION; INTRACELLULAR SPACE; LYSOSOME; MEMBRANE STRUCTURE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; QUANTITATIVE ANALYSIS; TRANSIENT EXPRESSION; ANIMAL; CELL CULTURE; DOG; DRUG EFFECTS; HEK293 CELL LINE; HT 29 CELL LINE; MCF 7 CELL LINE; METABOLISM; PHYSIOLOGY; TRANSPORT VESICLE;

ANIMALS; ANTIBODIES, MONOCLONAL; ATP-BINDING CASSETTE TRANSPORTERS; CAVEOLIN 1; CELLS, CULTURED; CHOLESTEROL; CLATHRIN; DOGS; ENDOCYTOSIS; HEK293 CELLS; HT29 CELLS; HUMANS; MCF-7 CELLS; METABOLIC NETWORKS AND PATHWAYS; NEOPLASM PROTEINS; PROTEIN BINDING; PROTEIN TRANSPORT; TRANSPORT VESICLES;

EID: 84928914150     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2015.04.011     Document Type: Article

References (47)

1. Litman T., Brangi M., Hudson E., Fetsch P., Abati A., Ross D.D., Miyake K., Resau J.H., Bates S.E. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J. Cell Sci. 2000, 113:2011-2021.
2. Cooray H.C., Blackmore C.G., Maskell L., Barrand M.A. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 2002, 13:2059-2063.
3. Jonker J.W., Smit J.W., Brinkhuis R.F., Maliepaard M., Beijnen J.H., Schellens J.H., Schinkel A.H. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. 2000, 92:1651-1656.
4. Maliepaard M., Scheffer G.L., Faneyte I.F., van Gastelen M.A., Pijnenborg A.C., Schinkel A.H., van De Vijver M.J., Scheper R.J., Schellens J.H. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001, 61:3458-3464.
5. Dietrich C.G., Geier A., Oude Elferink R.P. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 2003, 52:1788-1795.
6. Mizuno N., Suzuki M., Kusuhara H., Suzuki H., Takeuchi K., Niwa T., Jonker J.W., Sugiyama Y. Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice. Drug Metab. Dispos. 2004, 32:898-901.
7. Zhou S., Schuetz J.D., Bunting K.D., Colapietro A.M., Sampath J., Morris J.J., Lagutina I., Grosveld G.C., Osawa M., Nakauchi H., Sorrentino B.P. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 2001, 7:1028-1034.
8. Matsuo H., Takada T., Ichida K., Nakamura T., Nakayama A., Ikebuchi Y., Ito K., Kusanagi Y., Chiba T., Tadokoro S., et al. Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. Sci. Transl. Med. 2009, 1:5ra11.
9. van Herwaarden A.E., Wagenaar E., Merino G., Jonker J.W., Rosing H., Beijnen J.H., Schinkel A.H. Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol. Cell. Biol. 2007, 27:1247-1253.
10. Xia C.Q., Liu N., Yang D., Miwa G., Gan L.S. Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells. Drug Metab. Dispos. 2005, 33:637-643.
11. Basseville A., Tamaki A., Ierano C., Trostel S., Ward Y., Robey R.W., Hegde R.S., Bates S.E. Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter. Cancer Res. 2012, 72:3642-3651.
12. Erdei Z., Sarkadi B., Brózik A., Szebényi K., Várady G., Makó V., Péntek A., Orbán T.I., Apáti Á. Dynamic ABCG2 expression in human embryonic stem cells provides the basis for stress response. Eur. Biophys. J. 2013, 42:169-179.
13. Peng H., Qi J., Dong Z., Zhang J.T. Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells. PLoS One 2010, 5:e15276.
14. Bleau A.M., Hambardzumyan D., Ozawa T., Fomchenko E.I., Huse J.T., Brennan C.W., Holland E.C. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009, 4:226-235.
15. Stacy A.E., Jansson P.J., Richardson D.R. Molecular pharmacology of ABCG2 and its role in chemoresistance. Mol. Pharmacol. 2013, 84:655-669.
16. Özvegy-Laczka C., Várady G., Köblös G., Ujhelly O., Cervenak J., Schuetz J.D., Sorrentino B.P., Koomen G.J., Váradi A., Német K., Sarkadi B. Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface. J. Biol. Chem. 2005, 280:4219-4227.
17. Telbisz Á., Hegedüs C., Özvegy-Laczka C., Goda K., Várady G., Takáts Z., Szabó E., Sorrentino B.P., Váradi A., Sarkadi B. Antibody binding shift assay for rapid screening of drug interactions with the human ABCG2 multidrug transporter. Eur. J. Pharm. Sci. 2012, 45:101-109.
18. Heukers R., Vermeulen J.F., Fereidouni F., Bader A.N., Voortman J., Roovers R.C., Gerritsen H.C., van Bergen En Henegouwen P.M. Endocytosis of EGFR requires its kinase activity and N-terminal transmembrane dimerization motif. J. Cell Sci. 2013, 126:4900-4912.
19. Payne C.K., Jones S.A., Chen C., Zhuang X. Internalization and trafficking of cell surface proteoglycans and proteoglycan-binding ligands. Traffic 2007, 8:389-401.
20. Wakabayashi Y., Kipp H., Arias I.M. Transporters on demand: intracellular reservoirs and cycling of bile canalicular ABC transporters. J. Biol. Chem. 2006, 281:27669-27673.
21. Madshus I.H., Stang E. Internalization and intracellular sorting of the EGF receptor: a model for understanding the mechanisms of receptor trafficking. J. Cell Sci. 2009, 122:3433-3439.
22. Tateno H., Li H., Schur M.J., Bovin N., Crocker P.R., Wakarchuk W.W., Paulson J.C. Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity. Mol. Cell. Biol. 2007, 27:5699-5710.
23. Marchese A. Endocytic trafficking of chemokine receptors. Curr. Opin. Cell Biol. 2013, 27:72-77.
24. Doherty G.J., McMahon H.T. Mechanisms of endocytosis. Annu. Rev. Biochem. 2009, 78:857-902.
25. Dutta D., Williamson C.D., Cole N.B., Donaldson J.G. Pitstop 2 is a potent inhibitor of clathrin-independent endocytosis. PLoS One 2012, 7:e45799.
26. Cheng Z.J., Singh R.D., Sharma D.K., Holicky E.L., Hanada K., Marks D.L., Pagano R.E. Distinct mechanisms of clathrin-independent endocytosis have unique sphingolipid requirements. Mol. Biol. Cell 2006, 17:3197-3210.
27. Rejman J., Bragonzi A., Conese M. Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by lipo- and polyplexes. Mol. Ther. 2005, 12:468-474.
28. Van Amersfoort E.S., Van Strijp J.A. Evaluation of a flow cytometric fluorescence quenching assay of phagocytosis of sensitized sheep erythrocytes by polymorphonuclear leukocytes. Cytometry 1994, 17:294-301.
29. Yumoto R., Nishikawa H., Okamoto M., Katayama H., Nagai J., Takano M. Clathrin-mediated endocytosis of FITC-albumin in alveolar type II epithelial cell line RLE-6TN. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005, 290:L946-L955.
30. Schubert W., Frank P.G., Razani B., Park D.S., Chow C.W., Lisanti M.P. Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin in vivo. J. Biol. Chem. 2001, 276:48619-48622.
31. Puri V., Watanabe R., Singh R.D., Dominguez M., Brown J.C., Wheatley C.L., Marks D.L., Pagano R.E. Clathrin-dependent and -independent internalization of plasma membrane sphingolipids initiates two Golgi targeting pathways. J. Cell Biol. 2001, 154:535-547.
32. Le P.U., Nabi I.R. Distinct caveolae-mediated endocytic pathways target the Golgi apparatus and the endoplasmic reticulum. J. Cell Sci. 2003, 116:1059-1071.
33. Lamaze C., Chuang T.H., Terlecky L.J., Bokoch G.M., Schmid S.L. Regulation of receptor-mediated endocytosis by Rho and Rac. Nature 1996, 382:177-179.
34. Peng H., Dong Z., Qi J., Yang Y., Liu Y., Li Z., Xu J., Zhang J.T. A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy. PLoS One 2009, 4:e5676.
35. Ding R., Shi J., Pabon K., Scotto K.W. Xanthines down-regulate the drug transporter ABCG2 and reverse multidrug resistance. Mol. Pharmacol. 2012, 1:328-337.
36. Aust S., Obrist P., Jaeger W., Klimpfinger M., Tucek G., Wrba F., Penner E., Thalhammer T. Subcellular localization of the ABCG2 transporter in normal and malignant human gallbladder epithelium. Lab. Invest. 2004, 84:1024-1036.
37. Takada T., Suzuki H., Gotoh Y., Sugiyama Y. Regulation of the cell surface expression of human BCRP/ABCG2 by the phosphorylation state of Akt in polarized cells. Drug Metab. Dispos. 2005, 33:905-909.
38. Lampe M., Pierre F., Al-Sabah S., Krasel C., Merrifield C.J. Dual single-scission event analysis of constitutive transferrin receptor (TfR) endocytosis and ligand-triggered β2-adrenergic receptor (β2AR) or Mu-opioid receptor (MOR) endocytosis. Mol. Biol. Cell 2014, 25:3070-3080.
39. Özvegy-Laczka C., Laczkó R., Hegedus C., Litman T., Várady G., Goda K., Hegedus T., Dokholyan N.V., Sorrentino B.P., Váradi A., Sarkadi B. Interaction with the 5D3 monoclonal antibody is regulated by intramolecular rearrangements but not by covalent dimer formation of the human ABCG2 multidrug transporter. J. Biol. Chem. 2008, 283:26059-26070.
40. Pahara J., Shi H., Chen X., Wang Z. Dimerization drives PDGF receptor endocytosis through a C-terminal hydrophobic motif shared by EGF receptor. Exp. Cell Res. 2010, 316:2237-2250.
41. Rosenberg M.F., Bikadi Z., Chan J., Liu X., Ni Z., Cai X., Ford R.C., Mao Q. The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone. Structure 2010, 18:482-493.
42. Emi Y., Nomura S., Yokota H., Sakaguchi M. ATP-binding cassette transporter isoform C2 localizes to the apical plasma membrane via interactions with scaffolding protein. J. Biochem. 2011, 149:177-189.
43. Azuma Y., Takada M., Shin H.W., Kioka N., Nakayama K., Ueda K. Retroendocytosis pathway of ABCA1/apoA-I contributes to HDL formation. Genes Cells 2009, 14:191-204.
44. Ares G.R., Ortiz P.A. Dynamin2, clathrin, and lipid rafts mediate endocytosis of the apical Na/K/2Cl cotransporter NKCC2 in thick ascending limbs. J. Biol. Chem. 2012, 287:37824-37834.
45. Beemiller P., Hoppe A.D., Swanson J.A. A phosphatidylinositol-3-kinase-dependent signal transition regulates ARF1 and ARF6 during Fcgamma receptor-mediated phagocytosis. PLoS Biol. 2006, 4:e162.
46. Subauste M.C., Von Herrath M., Benard V., Chamberlain C.E., Chuang T.H., Chu K., Bokoch G.M., Hahn K.M. Rho family proteins modulate rapid apoptosis induced by cytotoxic T lymphocytes and Fas. J. Biol. Chem. 2000, 275:9725-9733.
47. Dinneen J.L., Ceresa B.P. Expression of dominant negative rab5 in HeLa cells regulates endocytic trafficking distal from the plasma membrane. Exp. Cell Res. 2004, 294:509-522.